These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795 [TBL] [Abstract][Full Text] [Related]
3. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. Jin Y; Ding K; Wang D; Shen M; Pan J Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577 [TBL] [Abstract][Full Text] [Related]
4. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. Gambacorti-Passerini C; Piazza R JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011 [No Abstract] [Full Text] [Related]
5. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
6. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234 [TBL] [Abstract][Full Text] [Related]
7. Hematological and molecular response evaluation of CML patients on imatinib. Gupta A; Prasad K J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739 [TBL] [Abstract][Full Text] [Related]
8. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia]. Usui N Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317 [TBL] [Abstract][Full Text] [Related]
9. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P; Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785 [TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124 [TBL] [Abstract][Full Text] [Related]
11. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia. Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743 [No Abstract] [Full Text] [Related]
12. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells. Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722 [TBL] [Abstract][Full Text] [Related]
13. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia. Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710 [No Abstract] [Full Text] [Related]
14. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792 [TBL] [Abstract][Full Text] [Related]
15. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844 [TBL] [Abstract][Full Text] [Related]
16. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity. Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486 [TBL] [Abstract][Full Text] [Related]
17. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907 [TBL] [Abstract][Full Text] [Related]
18. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498 [TBL] [Abstract][Full Text] [Related]
19. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase. Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437 [TBL] [Abstract][Full Text] [Related]